ASCO: HER2-targeted antibody drug conjugate shows strong anti-tumor activity and durable responses across multiple tumor types
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit ...